![]() |
市場調査レポート
商品コード
1797670
女性の健康に関するPOC検査の世界市場:製品タイプ・年齢・サンプルタイプ・検査タイプ・技術・用途・流通経路・エンドユーザー・地域別 (~2032年)Global Point-of-Care Testing for Women Health Market Research by Product, by Age, by Sample Type, by Test Type, by Technology, by Application, by Distribution Channel, by End User, and by Region Forecast till 2032 |
||||||
|
女性の健康に関するPOC検査の世界市場:製品タイプ・年齢・サンプルタイプ・検査タイプ・技術・用途・流通経路・エンドユーザー・地域別 (~2032年) |
出版日: 2025年07月16日
発行: Market Research Future
ページ情報: 英文 350 Pages
納期: 即納可能
![]() |
世界の女性の健康に関するPOC検査の市場規模は、2024年から2032年にかけてCAGR 6.26%で堅調に推移し、2032年には287億7,000万米ドルに成長すると予測されています。 女性の健康に関するPOC検査は、多目的で簡単にアクセスできる診断ツールであり、生殖の健康、感染症、妊娠関連合併症といった重大な状態に対して、即時かつ持ち運び可能な結果を提供します。当初は障害者向けに開発されたものですが、現在では病院、クリニック、自宅でも利用可能です。その迅速性に加え、価格の手頃さや信頼性の高さにより、予防医療全体や重症化前の早期医療介入における重要な役割を担うようになっています。
性感染症、尿路感染症、HPVといった女性に多い疾患が増加していることは、迅速な検査ツールの緊急性を浮き彫りにしています。POC検査は、迅速かつ信頼性の高い結果を提供することで、この課題に対応し、早期診断と介入を支援します。女性の健康は、タイムリーな治療とアクセス可能な検査ソリューションに大きく依存しており、感染症負担の増大が採用を後押ししています。
北米市場は、迅速かつ信頼性の高い検査に対する消費者需要を背景に拡大しています。高い認知度と整備された医療システムが追い風となり、病院のみならず在宅ケア環境でも幅広く利用されています。2023年の北米市場では、米国がトップで市場規模は57億3,544万米ドル、続いてカナダが8億8,972万米ドル、メキシコが4億2,632万米ドルとなりました。
欧州市場ではイノベーションが活発で、個別化医療への注目が高まっています。最先端の診断プラットフォームの利用が拡大しており、生殖の健康から慢性疾患に至るまで、疾病の早期発見が主な目的とされています。2023年には、ドイツが12億2,006万米ドル、英国が9億6,019万米ドル、フランスが7億7,511万米ドルで、欧州の上位3位を占めました。
アジア太平洋地域は、中国、インド、東南アジアにおける医療アクセス拡大を背景に、顕著な成長可能性を示しています。2023年には、中国(7億5,165万米ドル)、インド(6億3,481万米ドル)、日本(6億731万米ドル)が主要市場を形成しました。妊娠関連合併症や慢性疾患の増加が、POCTソリューションへの依存度を高めています。
当レポートでは、世界の女性の健康に関するPOC検査の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。
Global Point-of-Care Testing for Women Health Market Research by Product (Instruments/ Devices, Reagents & Kits, Consumables), by Age (Adolescent, Adult, Geriatric), by Sample Type (Serum, Plasma, White Blood, Urine, Others), by Test Type (Testosterone Test, Estradiol Test, Anti- Mullerian Hormone Test, Prolactin Test, Progesterone Test, Follicle-Stimulating Hormone Test, Luteinizing Hormone Test, B-hCG Test, Others), by Technology (Colloidal Gold Lateral Flow Assays, Fluorescence Immunoassays, Lab-on-a-Chip, Others), by Application (Gestational Diabetes, Vaginal Infection, Urinary Tract Infection, Cervical Cancer or Pre-Cancerous Conditions, Hemoglobin Deficiency, Breast Cancer, Thyroid Disease, Sexually Transmitted Infections, Fertility Conditions, Pregnancy Testing, Others), by Distribution Channel (Offline, Online), by End User (Hospitals, Diagnostic Laboratories, Home Settings, Others), and by Region (North America, Europe, Asia Pacific, Rest of the World) Forecast till 2032
Industry Overview
The Global Point-of-Care Testing for Women's Health Market is forecasted to expand to USD 28.77 billion by 2032, reflecting a steady 6.26% CAGR during 2024-2032. POCT for women's health is a multipurpose, easy-to-access diagnostic tool giving immediate and on-the-go results of critical conditions, such as reproductive health, infectious diseases, and pregnancy-related complications. Originally intended for the disabled, these tests are also accessible at hospitals, clinics, or simply at home. Their rapidity, and at the same time, good affordability and reliability allow them to become keys in the whole preventive care and early medical intervention process serious cases.
Growing cases of sexually transmitted infections, urinary tract infections, and HPV among women highlight the urgent need for rapid detection tools. POC testing addresses this gap with quick and reliable results, supporting early diagnosis and intervention. The rising infection burden is propelling adoption, as women's health outcomes depend on timely treatment and accessible testing solutions.
Key Company Development
Swiss Precision Diagnostics GmbH has demonstrated consistent innovation in advancing diagnostic solutions for women's health. In August 2023, the company launched the Clearblue Menopause Stage Indicator, a first-of-its-kind home-use product that evaluates menopause stages by integrating urinary FSH measurements with age and cycle data. This innovation empowers women with greater understanding of reproductive transitions, fostering informed health decisions. Complementing this milestone, SPD in August 2020 implemented the Matrix Gemini LIMS to optimize data management in pregnancy studies. This technology enhanced accessibility, streamlined laboratory workflows, and improved biobank operations, reflecting the company's strong emphasis on digital transformation. These strategic moves reinforce SPD's leadership in combining product innovation and advanced technologies to deliver precision-driven women's health diagnostics.
Major players in the global point-of-care testing for women health market are Swiss Precision Diagnostics GmbH (SPD), Wondfo, Church & Dwight Co., Inc., Hangzhou Singclean, Medical Products Co., Ltd., W.H.P.M., Inc., SEKISUI Diagnostics, Innovita Biological Technology Co., Ltd., Yangzhou VIOMED, Cofoe Medical Technology Co., Ltd., and Chungdo Pharm Co., Ltd.
Report Attribute Details
Market Size 2023 USD 16,627.22 Million
Market Size 2032 USD 28,768.16 Million
CAGR (2024-2032) 6.26%
Base Year 2023
Market Forecast Period 2024-2032
Historical Data 2019-2024
Industry Segmentations CAGR (2024-2032)
By Product: Instruments/ Devices - 7.72%, Reagents & Kits - 5.97%.
By Age: Adolescent - 8.18%, Adult - 6.20%.
By Sample Type: Serum - 5.27%, Plasma - 4.30%.
By Test Type: Testosterone Test - 4.12%, Estradiol Test - 3.53%.
By Technology: Colloidal Gold Lateral Flow Assays - 7.19%, Fluorescence Immunoassays - 5.46%.
By Application: Gestational Diabetes - 5.34%, Vaginal Infection - 4.08%.
By Distribution Channel: Offline - 5.49%, Online - 7.35%.
By End User: Hospitals - 5.42 %, Diagnostic Laboratories - 6.96%.
The women's health POCT market in North America rides on the back of consumer demand for quick and reliable testing. High awareness in conjunction with well-organized healthcare systems acts as a springboard for wide use in hospital as well as home-care environments. In 2023, North America's market was led by the US, followed by Canada and Mexico, with respective market values of USD 5,735.44 million, USD 889.72 million, and USD 426.32 million.
Innovation is thriving in the European market, and there is an increasing emphasis on personalized medicine. The use of cutting-edge diagnostic platforms is growing, with the primary objective being early detection of diseases that range from reproductive health to chronic conditions. In 2023, Germany, the UK, and France were the top three European markets, contributing USD 1,220.06 million, USD 906.19 million, and USD 775.11 million.
Asia-Pacific demonstrates remarkable growth potential, propelled by expanding healthcare access in China, India, and Southeast Asia. In 2023, the APAC region China, India, and Japan, is the leading market, with market sizes of USD 751.65 million, USD 634.81 million, and USD 607.31 million. A rising incidence of pregnancy-related complications and chronic illnesses is driving reliance on POCT solutions.
Markets in the Middle East, Africa, and South America are witnessing steady adoption of POCT, largely due to limited access to traditional laboratory infrastructure. Portable diagnostic technologies are emerging as vital tools in addressing reproductive health challenges.